U.S. Markets open in 3 hrs 54 mins
S&P Futures
2,476.25
+2.25 (+0.09%)Dow Futures
21,579.00
+19.00 (+0.09%)
| Previous Close | 323.52 |
| Open | 325.21 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 324.58 - 326.88 |
| 52 Week Range | 268.25 - 326.88 |
| Volume | 1,927,430 |
| Avg. Volume | 1,224,107 |
| Net Assets | 19.04B |
| NAV | 317.86 |
| PE Ratio (TTM) | N/A |
| Yield | 1.14% |
| YTD Return | 5.72% |
| Beta (3y) | 1.00 |
| Expense Ratio (net) | 0.25% |
| Inception Date | 1995-05-04 |
- Market Realist•2 days ago
Behind Abiomed’s Plans to Create a Greater Awareness of Impella
To target patients across communities, Abiomed (ABMD) has been developing a hub-and-spoke model with hospitals.
- GuruFocus.com•8 days ago
Pachira Investments Inc. Buys Vanguard Short-Term Bond, Sells SPDR MidCap Trust Series I
Investment company Pachira Investments Inc. buys Vanguard Short-Term Bond, sells SPDR MidCap Trust Series I during the 3-months ended 2017-06-30, according to the most recent filings of the investment ...
- Market Realist•23 days ago
What Can We Expect from United Therapeutics’ Tyvaso in 2017?
In 2016, United Therapeutics’ (UTHR) Tyvaso reported revenues of ~$404.0 million, which reflected an ~15.0% decline year-over-year.
